3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
52
Lung Neoplasms
11
Breast Neoplasms
11
Head and Neck Neoplasms
8
Neoplasms
5
Neoplasm Metastasis
4
NSCLC
4
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Colorectal Neoplasms
3
Carcinoma
3
Brain Neoplasms
3
Respiratory Tract Diseases
2
Neoplasms, Squamous Cell
2
Carcinoma, Squamous Cell
2
Adenocarcinoma of Lung
2
Urinary Bladder Neoplasms
1
Thoracic Neoplasms
1
Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC
1
Small Cell Lung Carcinoma
1
Respiratory Tract Neoplasms
1
Pancreatic Neoplasms
1
Non-Metastatic Prostate Cancer
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma
1
Lung Diseases
1
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Gefitinib
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA